- Home
- BETR vs KOD Comparison
BETR vs KOD Comparison
Compare BETR & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BETR
- KOD
- Stock Information
- Founded
- BETR 2014
- KOD 2009
- Country
- BETR United States
- KOD United States
- Employees
- BETR N/A
- KOD N/A
- Industry
- BETR Finance: Consumer Services
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BETR Finance
- KOD Health Care
- Exchange
- BETR Nasdaq
- KOD Nasdaq
- Market Cap
- BETR 203.4M
- KOD 198.4M
- IPO Year
- BETR N/A
- KOD 2018
- Fundamental
- Price
- BETR $17.93
- KOD $10.20
- Analyst Decision
- BETR
- KOD Hold
- Analyst Count
- BETR 0
- KOD 4
- Target Price
- BETR N/A
- KOD $11.75
- AVG Volume (30 Days)
- BETR 51.8K
- KOD 673.8K
- Earning Date
- BETR 08-13-2025
- KOD 08-13-2025
- Dividend Yield
- BETR N/A
- KOD N/A
- EPS Growth
- BETR N/A
- KOD N/A
- EPS
- BETR N/A
- KOD N/A
- Revenue
- BETR $130,672,000.00
- KOD N/A
- Revenue This Year
- BETR $55.38
- KOD N/A
- Revenue Next Year
- BETR $71.18
- KOD N/A
- P/E Ratio
- BETR N/A
- KOD N/A
- Revenue Growth
- BETR 69.42
- KOD N/A
- 52 Week Low
- BETR $7.71
- KOD $1.92
- 52 Week High
- BETR $21.80
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- BETR 65.01
- KOD 65.75
- Support Level
- BETR $12.74
- KOD $8.77
- Resistance Level
- BETR $18.47
- KOD $11.30
- Average True Range (ATR)
- BETR 1.44
- KOD 0.99
- MACD
- BETR 0.29
- KOD 0.02
- Stochastic Oscillator
- BETR 90.58
- KOD 73.24
About BETR Better Home & Finance Holding Company
Better Home & Finance Holding Co is a digital-first homeownership company whose services include mortgage, real estate, title, and homeowners insurance. The company has combined technology innovation and fresh thinking with a deep customer focus with the goal of revolutionizing the homeownership industry.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.